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Abstract 
of CF-causing mutations it might be prudent to wait 
until a greater proportion of CF carriers can be detected 
in the South African CF population, before offering the 
test. Unless patients are adequately coun selled and 
made aware of the limitations of the test, a great deal of 
anxiety will be caused. 
W/e are grateful to: Dr I Reef and Dr J Perrifor, from the 
CF clinic at Johannesburg H ospital, and the Genetic 
Services sisters of the Department of National Health and 
Population Development for their co-operation in referring 
patients and their relatives. We thank the H. E. Griffin 
Charitable Trust (through the University of the Witwaters-
rand) for support. 
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The frequency of the delta F508 mutation in the cystic 
fibrosis genes of71 unrelated South African cystic 
fibrosis patients 
J. S. HERBERT, A. E. RETIEF 
The common ~F508 mutation is present in 
approximately 70% of mutant cystic fibrosis (CF) 
genes of European and North American popula-
tions. The frequency of the ~508 mutation has 
been established for two groups of South African 
CF subjects. The mutation was found to be present 
in 82% and 53% of CF genes of white and coloured 
(Le. of mixed ancestry) subjects respectively. 
These findings assist in providing appropriate 
counselling to individuals who have a family his-
tory of CF and in defining laboratory strategies for 
the establishment of an efficient genetic service for 
cystic fibrosis. 
S Air Med J 1992; 82: 13 -15 
Cystic fibrosis (CF) is a severe autosom al recessive disease common in Caucasian populations. The incidence of CF in the white (Caucasian) popu-
lation of South Africa is approximately 1112 000 live 
births; for the coloured population (i. e. people of mixed 
ancestry) the incidence is approximately 1/ 1 200 live 
births. ! CF is characterised by progressive lung disease 
and pancreatic insufficiency. The clinical expression of 
CF is diverse. 
The gene responsible for CF is located on the long 
arm of human chromosome 7.2,3 This gene codes for the 
cystic fibro sis transm embrane conductance regulator 
(CITR). Molecular analysis of CF genes has revealed 
that there is a common mutation present in approxi-
mately 70 % of mutant CF genes. This mutation is 
termed the &508 mutation and is a 3 base pair deletion 
which results in the loss of a phenylalanine residue at 
position 508 in the CFTR protein .... • The frequency 
with which the &508 mutation occurs varies between 
different population groupS.7 Many mutations other 
than the ~508 have been identified in the CF gene. 
The prevalence of these mutations is low. ' 
Departnlent of Human Genetics, University of Stell en bosch, 
Parowvallei, CP 
Prior to the identification and characterisation of the 
CF gene, DNA-based diagnosis of CF was performed 
by linkage studies in CF families with restriction frag-
m ent length polymorphisms (RFLPs) linked to the CF 
locus. This approach is indirect, as a specific mutation is 
not assayed. Linkage studies have been successfully used 
to diagnose prenatal CF and determine carrier status 
within families .' The discovery of identifiable mutations 
in the CF gene provides the opportunity for directly 
identifying the mutations causing the disease in specific 
subjects. The &508 mutation can easily be detected in 
a mutant CF gene."!O In practice, the m ost efficient 
metho d of providing a DNA-based diagno stic 
service for CF is by assaying for the presence of the 
~F508 mutation in CF genes and employing RFLP 
studies to follow the inheritance of the other mutations. 
Within the context of a routine diagnostic service it is 
impractical to search mutant CF genes for mutations 
other than &508. 
J. S. HERBERT, M.SC. 
A. E. RETIEF, PH.D. 
Accepted: 18 ,\-tar 1992. 
Reprint requests: J. S. Herben, Dept of Human Generics, Universiry of 
Stellenbosch, PO Box 19063, T ygerberg, 7505 RSA. 
Cld 
~ C CD I Q.C 
ca· 
a.. C 
.. e 
CD..! 
-C 
.2J 
--~1 C c 
14 VOL 82 JULIE 1992 
SAMJ 
In order to provide a DNA-based diagnostic service 
for CF, it is necessary to know the frequency with which 
the ~508 mutation occurs in the mutant CF genes of 
the population to be served. The frequency of the muta-
tion was established for a group of 7 1 unrelated South 
African CF subjects from both white and coloured 
ethnic groups. The genotypes of these subjects were also 
established. 
Subjects and methods 
Subjects studied 
Seventy-one unrelated subjects diagnosed as having CF 
were tested for the presence of the ~508 mutation in 
their CF genes. The subjects were divided into two 
groups according to their ethnic origin. The white group 
had 57 subjects and the coloured (mixed race) group 14 
subjects. The subjects in the coloured group came from 
the Western Cape; the white subjects were predomi-
nandy from Natal and the Western Cape. 
DNA analysis 
DNA was isolated from peripheral blood samples ll 
obtained from subjects by venepuncture. 
Two methods of detecting ~F508 were employed. 
Both methods used the polymerase chain reaction 
(PCR) for the amplification of the exon 10 gene frag-
ment which includes the &508 mutation. All oligonu-
cleotides used, in both methods, were obtained com-
mercially. 
Method 1 
The exon 10 gene fragment, including the &508 muta-
tion, was amplified by the PCR. The sequence of 
primers used for DNA amplification and the allele-
specific oligonucleotide (ASO) probes used are those 
described by Riordan er at. ' PCR products were sepa-
rated by agarose gel electrophoresis and transferred to a 
membrane by means of the Southern transfer technique. 
Membranes were hybridised with radio-labelled ASO 
probes . Autoradiography was used to detect positive 
hybridisation of ASO probes to amplified DNA. Positive 
hybridisation of the ASO probe for the normal allele 
indicated that the ~F508 mutation was not present. 
Positive hybridisation of the ASO probe, specific for the 
~F508 mutation, indicated the presence of the muta-
tion. Hybridisation of both ASO probes to amplified 
DNA from one subject indicated that the subject carried 
one CF gene with the ~508 mutation and one without. 
A subject with this genotype is heterozygous for the 
&508 mutation. 
Method 2 
The PCR was used to amplify the exon 10 gene frag-
ment, including the ~F508 mutation site, to produce 
either 50 or 47 base pair products . l o A 50 base pair 
product is produced when the &508 mutation is absent 
from the CF gene and a 47 base pair product when the 
mutation is present. PCR products were separated by 
polyacrylamide gel electrophoresis. Analysis was per-
formed after the gels were stained with ethidium bro-
mide. 
Subjects who do not carry the ~F508 mutation in 
either of their CF genes are identified by the production 
of only a 50 base pair PCR product. Subjects who are 
heterozygous for the ~508 mutation show both a 50 
and a 47 base pair PCR product. Subjects who are 
homozygous for the ~F508 mutation show a 47 base 
pair PCR product only. 
Results 
The number and proportion (relative to other muta-
tions) of &508 mutations in 142 mutant CF genes are 
presented in Table I. The subjects studied were grouped 
according to race. The incidence of the &508 mutation 
in the white group was found to be 82% and 53% in the 
coloured population. 
TABLE I. 
Number and proportion of the ~F508 mutation in 142 
mutant CF genes from 71 cystic fibrosis patients 
Frequency of No. of 
mutations in CF genes CF 
Ethnic group ~F508 Other genes 
White 0,82 (94) 0,18 (20) 114 
Coloured 0,53 (15) 0,47 (13) 28 
Total 0,77 (109) 0,23 (33) 142 
, 'Other' refers to mutations in CF genes other than ~F508 mutation. The number 
of CF genes is indicated in parenthesis. 
The analyses perfonned made it possible to establish 
the genotypes of the subjects studied. These genotypes 
were constructed with regard to the presence of the 
~F508 mutation in CF genes . Genotypes of the CF 
subjects studied are presented in Table II. Sixty-eight 
per cent of white and 21 % of coloured subjects were 
found to be homozygous for the &508 mutation; 28% 
of white and 64% of coloured subjects were found to be 
heterozygous for the mutation. Four per cent of white 
and 15% of coloured subjects were found not to have 
the &508 mutation in either of their CF genes. 
TABLE II. 
Genotypes of 71 cystic fibrosis subjects 
No. of CF subjects per genotype 
Ethnic ~F508/ ~F508/ Other'/ 
group ~F508 other' other' 
White 39 (68) 16 (28) 2 (4) 
Coloured 3 (21) 9 (64) 2 (15) 
Total 42 (59) 25 (35) 4 (6) 
* 'Other' refers to mutations in CF genes other than ~F508 mutation . 
Percentages are indicated in parenthesis. 
Discussion 
No. of 
subjects 
57 
14 
71 
The frequency of the ~F508 mutation in mutant CF 
genes of white CF subjects is 82%. This figure is consis-
tent with the findings of other studies done on white 
subjects. 7 The frequency of the mutation in the coloured 
group was found to be 53 % . Although the coloured 
group was smaller than the white group, there is a signifi-
cant difference in the frequency of the ~F508 mutation 
in mutant CF genes (x' = 10,53; 0,01 > P < 0,001). 
Without examining the specific mutations present in 
the CF genes of coloured subjects '.'lithout &508 muta-
tion, the reasons for the difierence in frequency must 
remain a maner of conjecture. However, the observed 
difference could be anributed to the size of the coloured 
sample or to the flow of Caucasian genes into the 
coloured population. 
The genotypes of the CF subjects in both groups 
provide valuable infonnation for the implementation of 
a diagnostic service. Each CF subject studied represents 
a proband of a family who may seek a DNA-based diag-
nostic test, e.g. prenatal diagnosis of CF. \'\'here the 
proband is homozygous for the ~F508 mutation, a 
direct assay of the mutations causing the disease is pos-
sible. In the group studied, 68% of white families and 
21 % of coloured families fall into this category. For 
those families in which the proband is heterozygous for 
the LU'S08 mutation, the most efficient approach to a 
molecular diagnosis is to combine the assaying of the 
LU'S08 mutation with RFLP studies. The RFLP studies 
establish the inheritance pattern of the non-~FS08 
mutation in the family. In those cases where the 
proband does not carry a ~F508 mutation in either 
m u tant CF gene, it is necessary to rely on RFLP 
studies. Only 6% of all subjects studied fall into the 
latter category. In order to perform predictive analyses 
using RFLP studies it is essential to trace the inheri-
tance of CF genes from both parents to an affected 
child. All three subjects must therefore be available for 
analysis. 
The findings of this study not only assist in defining 
laboratory strategies for the diagnosis of CF but also 
provide valuable information for counselling the indivi-
dual with a positive family history of CF. The carrier 
status of the members of an extended family can be 
determined either by direct assay for the LU'508 muta-
tion, or by the use of RFLP studies for CF mutation 
tracking. Knowing the carrier status of individuals with 
a positive family history of CF is imponant when these 
individuals are of reproductive age so that appropriate 
genetic counselling can be provided as to the risk of pro-
ducing offspring with CF. 
Individuals who have a positive family history of CF 
and are not carriers of a CF mutation can be reassured 
that there is no risk of producing offspring with CF . The 
spouse of a CF carrier should be encouraged to have 
hislher carrier status determined as such couples have 
an increased risk for offspring with CF. D irect assay of 
the ~F508 mutation provides a means of establishing 
the carrier status of individuals who have no family his-
tory of CF. H owever, the absence of the LU'508 m uta-
tion in both CF genes does not exclude an individual 
from being a carrier. This is due to the frequency of the 
LU'508 mutation in mutant CF genes being less than 
100%. The chance of being a carrier is calculated from 
the theoretical carrier frequency, modified for the speci-
fic population group of the individual tested. The modi-
fied chance of being a carrier after exclusion of the 
~508 mutation is presented in Table III. 
TABLE III. 
Modified chance of an individual being a carrier of a CF 
mutation after exclusion of the .1F508 mutation 
Chance of carrying a CF mutation 
Prior to After excl usion 
Ethrric group .1F508 test' of .1F508 
White 1 in 20 1 in 111 
Coloured 1 in 55 1 in 117 
• Theoretical value based on prevalence of CF in specific populations. 
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The exclusion of the presence of the ~FS08 mutation 
in the CF genes of the spouse of a known carrier of a 
CF mutation modifies the risk of the' couple's offspring 
having CF. The modified risks of producing offspring 
with CF are presented in Table IV. 
TABLE IV. 
Risk of producing offspring affected with CF by a CF 
carrier and a spouse for whom the .1F508 mutation has 
been excluded 
Ethnic group 
White 
Coloured 
Risk of producing CF offspring 
Prior to 
.1F508 test' 
1 in 92 
1 in 220 
After exclusion 
of .1F508* 
1 in 51 2 
1 in 468 
~Risk calculation: chance of a known carrier passing a mutant CF gene to their 
offspring, 0,50; multiplied by the carrier frequency or modified carrier frequency 
for a specific population group; multiplied chance of passing a CF mutant gene to 
their offspring, 0,50. 
The modified chance of being a carrier of a mutation 
in a CF gene and the risk of producing offspring affect-
ed with CF after the exclusion of the ~S08 mutation 
are similar for both the white and coloured population 
groups. This is due to the combined effect of the fre-
quency of the ~F508 mutation in CF genes and the 
theoretical carrier frequencies in these two groups. 
We wish to thank the Cape Provincial Administration, 
the University of Stellenbosch and the Genetic Services 
of the Department of National Health and Population 
Development for funding this srudy and for the use of 
facilities. 
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